Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.48 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 14/20 | 0.48 |
| ▸ | FLT3 | P36888 | 14/20 | 0.48 |
| ▸ | KIT | P10721 | 4/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | MARK3 | P27448 | 1/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.45 |
| ▸ | SIK1 | P57059 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | MELK | Q14680 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.45 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.45 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.45 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.45 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918823 | 0.99 | CHEK1 (0.49) | ULK1ULK2CHEK1FLT3KIT | |
| SCHEMBL1918968 | 0.94 | ULK1 (0.55) | ULK1ULK2CHEK1FLT3KIT | |
| SCHEMBL3339984 | 0.90 | STK17A (0.51) | ULK1ULK2CHEK1FLT3KIT | |
| SCHEMBL1917610 | 0.89 | CHEK1 (0.50) | ULK1ULK2CHEK1FLT3KIT | |
| SCHEMBL1917790 | 0.89 | TYRO3 (0.50) | ULK1ULK2CHEK1FLT3KIT | |
| SCHEMBL1918098 | 0.88 | ULK1 (0.51) | ULK1ULK2CHEK1FLT3KIT | |
| SCHEMBL1917630 | 0.87 | TYRO3 (0.49) | ULK1ULK2CHEK1FLT3KIT | |
| SCHEMBL3283998 | 0.87 | PRKCQ (0.55) | ULK1ULK2CHEK1FLT3KIT | |
| SCHEMBL3284417 | 0.87 | CHEK1 (0.51) | ULK1ULK2CHEK1FLT3KIT | |
| SCHEMBL3283636 | 0.86 | CHEK1 (0.53) | ULK1ULK2CHEK1FLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | disclosed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| EP-2090571-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | ULK1 1959/4885ULK2 2040/4885CHEK1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.